Why the study?
Does sitagliptin improve glycemic control, renoprotective effects, and beta-cell function in Japanese patients with type 2 diabetes mellitus without a history of cardiovascular disease?
Population
Japanese patients with T2DM without a history of CVD (n = 17 sitagliptin, n = 9 control)
Comparison
Sitagliptin 50 mg monotherapy or combination therapy vs placebo monotherapy or combination therapy
Follow-up
Ten years
Key result
Sitagliptin treatment for 10 years in patients with type 2 diabetes mellitus significantly improved beta-cell function and reduced albuminuria, suggesting long-lasting renoprotective and islet-protective effects.
Authors
Loading...
May support long-term renoprotection and β-cell preservation with early sitagliptin in T2DM; leaves open confirmation in randomized trials.
RCT (n=52)
Open-label
Randomized
No
Does sitagliptin improve glycemic control, renoprotective effects, and beta-cell function in Japanese patients with type 2 diabetes mellitus without a history of cardiovascular disease?
Ten-year treatment with sitagliptin in T2DM patients without prior CVD provides sustained renoprotective and beta-cell protective effects.
Sachiko Hattori (2021) conducted an RCT in Type 2 diabetes mellitus (n=52). Sitagliptin vs. Placebo was evaluated on Change in urinary albumin excretion (ACR) and HOMA-β. Sitagliptin treatment for 10 years in patients with type 2 diabetes mellitus significantly improved beta-cell function and reduced albuminuria, suggesting long-lasting renoprotective and islet-protective effects.